Research programme: neuropilin-1 receptor antagonists - Trizell
Alternative Names: EG0048; EG012; EG012-014; EG01257; EG014; EG3287Latest Information Update: 23 Nov 2012
At a glance
- Originator Ark Therapeutics
- Class Small molecules
- Mechanism of Action Angiogenesis inhibitors; Neuropilin-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 08 Nov 2012 Discontinued - Preclinical for Solid tumours in United Kingdom (unspecified route)
- 22 May 2012 Preclinical development is ongoing in United Kingdom
- 11 Mar 2011 The neuropilin-1 receptor antagonists programme is available for licensing \www.arktherapeutics.com\